Retrospective analysis evaluates treatment efficacy and toxicity in advanced head and neck cancers, suggesting individualized palliative approaches.
Objectives: The study aims to evaluate the clinical efficacy, toxicity profile, radiobiological implications, and tumour response of four commonly used palliative hypofractionated regimens in this setting. Material and Methods: Retrospective analysis was conducted on 102 patients treated with one of four regimens: 20 Gy/5# daily, 20 Gy/5# weekly, 30 Gy/10# daily, or 50 Gy/16#. Biologically effective dose (BED) and equivalent dose in 2 Gy fractions (EQD2) values were calculated using the linear-quadratic model. Outcomes included symptom relief, tumour response, toxicity, and follow-up. Results: Most patients were male (90.2%), with a mean age of 53.5 years. Oral cavity (53.9%) and larynx (24.5%) were the predominant sites. Patients receiving 50 Gy/16# achieved the highest tumour response (95%) and best symptom relief (100% for pain and dysphagia) but had the highest toxicity and treatment interruptions (85%). The 30 Gy/10# regimen demonstrated comparable tumour response (84%) with significantly fewer toxicities and a median follow-up of 10.5 months. The 20 Gy/5# daily regimen provided moderate symptom relief (70–78%), minimal toxicity, and the fewest treatment interruptions with a median follow-up of 9.4 months. The 20 Gy/5# weekly regimen was well tolerated but yielded the lowest response rates across all parameters (pain relief 50%, hoarseness 33%, bleeding control 40%). Conclusion: In a high-volume Indian tertiary care centre setting, 30 Gy/10# offers an excellent balance of symptom control and tolerability. Higher-dose regimen with 50 Gy/16# should be reserved for fit patients with longer life expectancy. The 20 Gy/5# daily regimen remains a practical and low-toxicity choice for frail patients, while the weekly regimen may be reserved for the most unfit. These findings underscore the need for individualized, context-sensitive palliative strategies based on patient fitness, expected survival, and institutional workload.
No takes yet. Share an insight, caveat, or question.
Daljit et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: